Pancreatic Cancer Clinical Trials in Denver

Showing 121-140 of 142 trials

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Pancreatic CancerThromboembolism

Gary Morrow400 participantsStarted Oct 2002

Mobile, Alabama, United States • Denver, Colorado, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPhase 2< 1 mile

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

NCT01232829

This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.

Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer

National Cancer Institute (NCI)18 participantsStarted Oct 2010

Aurora, Colorado, United States • Denver, Colorado, United States • Baltimore, Maryland, United States

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Pancreatic Cancer Trials in Other Cities

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

Pancreatic Cancer Serum and DNA Repository

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Other Conditions in Denver